MAGEA1 and melanoma: In a completed, but unreported, study, several MAGE family members (i.e. MAGE-A1, MAGE-A3, MAGE-A4, MAGE-A10 and MAGE-C2) were targeted simultaneously in melanoma patients using a peptide vaccine.